Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Phase 1 Terminated
18 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Phase 1 Terminated
4 enrolled
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1 Terminated
10 enrolled
MK-3475-023
Phase 1 Terminated
77 enrolled 23 charts
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Phase 1 Terminated
8 enrolled 10 charts
RID
Phase 1 Terminated
12 enrolled
UF-BMT-MRD-101
Phase 1 Terminated
11 enrolled 3 charts
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Phase 1 Terminated
18 enrolled
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
13 enrolled 7 charts
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
Phase 1 Terminated
6 enrolled
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
Phase 1 Terminated
24 enrolled
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
17 enrolled
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
Phase 1 Terminated
7 enrolled
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 1 Terminated
5 enrolled
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
Phase 1 Terminated
8 enrolled
Lenalidomide After Allo Transplant
Phase 1 Terminated
1 enrolled
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Phase 1 Terminated
8 enrolled
Lenalidomide and Paclitaxel in Prostate Cancer
Phase 1 Terminated
17 enrolled
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
2 enrolled
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Phase 1 Terminated
9 enrolled
TAIL
Phase 1 Terminated
2 enrolled
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Phase 1 Terminated
5 enrolled
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Phase 1 Terminated
6 enrolled
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Phase 1 Terminated
1 enrolled
AZALE
Phase 1 Terminated
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
Phase 1 Terminated
1 enrolled
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Terminated
3 enrolled
Lenalidomide In Patients With Acute Myeloid Leukemia
Phase 1 Terminated
14 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Phase 1 Terminated
40 enrolled